{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:58:24Z","timestamp":1766516304761,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.urolonc.2022.10.019","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T16:15:29Z","timestamp":1668269729000},"page":"109.e1-109.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer"],"prefix":"10.1016","volume":"41","author":[{"given":"Mar\u00eda Teresa","family":"Melgarejo Segura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Morales Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaiza","family":"Y\u00e1\u00f1ez Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Arrabal Polo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"G\u00f3mez Lechuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Pareja V\u00edlchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Arrabal Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2022.10.019_bib0001","unstructured":"Professionals SO. EAU Guidelines: Non-muscle-invasive Bladder Cancer. Uroweb, https:\/\/uroweb.org\/guideline\/non-muscle-invasive-bladder-cancer\/; [accessed 08.11.21]."},{"key":"10.1016\/j.urolonc.2022.10.019_bib0002","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence Rate and Cost Consequence of the Shortage of Bacillus Calmette-Gu\u00e9rin Connaught Strain for Bladder Cancer Patients","volume":"7","author":"Ourfali","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0004","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","article-title":"The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive Bladder Cancer: a systematic review","volume":"60","author":"Lammers","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0006","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.7717\/peerj.2309","article-title":"Investigation of the mechanisms of action behind Electromotive Drug Administration (EMDA)","volume":"4","author":"Kos","year":"2016","journal-title":"PeerJ"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0007","first-page":"4912","article-title":"Electromotive versus Passive Diffusion of Mitomycin C into human bladder wall: concentration-depth profiles studies","volume":"59","author":"Stasi","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0008","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). 2017;155. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0009","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","article-title":"Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma","volume":"21","author":"Colombo","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jconrel.2014.04.049","article-title":"Single compartment drug delivery","volume":"0","author":"Cima","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0011","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1470-2045(20)30147-9","article-title":"Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial","volume":"21","author":"Kleinmann","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0012","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000502663","article-title":"Intravesical treatment with electro-mediated administration of mytomicin c as prophylaxis for intermediate and high-risk nonmuscle-invasive Bladder Cancer: a retrospective multicenter study","volume":"103","author":"Carando","year":"2019","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0013","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.purol.2020.03.005","article-title":"The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: a systematic review","volume":"30","author":"Carando","year":"2020","journal-title":"Progr\u00e8s en Urologie"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0014","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/02656736.2016.1142618","article-title":"Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate\u2013high-risk non-muscle-invasive bladder cancer","volume":"32","author":"Sousa","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0015","doi-asserted-by":"crossref","first-page":"498.e13","DOI":"10.1016\/j.urolonc.2020.12.025","article-title":"Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage","volume":"39","author":"Grimberg","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0016","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0017","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.clgc.2020.11.002","article-title":"Second-line conservative device-assisted intravesical treatment in selected patients with recurrent high-risk non-muscle-invasive Bladder Cancer","volume":"19","author":"Di Gianfrancesco","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0018","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0019","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-180191","article-title":"Hyperthermic Intravesical Chemotherapy for BCG Unresponsive non-muscle invasive Bladder Cancer Patients","volume":"4","author":"de Jong","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0020","doi-asserted-by":"crossref","first-page":"62.e13","DOI":"10.1016\/j.urolonc.2021.07.019","article-title":"Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer","volume":"40","author":"Pijpers","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0021","first-page":"287","article-title":"Outcomes and complications of Hyperthermic IntraVesical Chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Gu\u00e9rin treatment failure","volume":"73","author":"Chiancone","year":"2020","journal-title":"Cent European J Urol"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0022","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u2018BCG failure\u2019 non muscle invasive bladder cancer: 3\u2009years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0023","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.prp.2017.07.026","article-title":"Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy)","volume":"213","author":"Pierconti","year":"2017","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0024","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/cncy.21957","article-title":"The risk of malignancy of atypical urothelial cells of undetermined significance in patients treated with chemohyperthermia or electromotive drug administration","volume":"126","author":"Pierconti","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000052419","article-title":"Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion","volume":"39","author":"Colombo","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0026","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2013.12.018","article-title":"Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort","volume":"66","author":"Aziz","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.10.019_bib0027","doi-asserted-by":"crossref","unstructured":"Guerrero-Ramos F, Gonz\u00e1lez-Padilla DA, Gonz\u00e1lez-D\u00edaz A, de la Rosa-Kehrmann F, Rodr\u00edguez-Antol\u00edn A, Inman BA, et al. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J Urol. 2022 Jan 17.","DOI":"10.1007\/s00345-022-03928-1"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922003982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922003982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:26:52Z","timestamp":1761042412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922003982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1078143922003982"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.019","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}